Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin announced positive pivotal data for ziftomenib, an oral menin inhibitor, in patients with relapsed/refractory (R/R) NPM1...
Home/KnloSights/Clinical Trial Updates/Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AML